Description

Simple

A medication used during MRA diagnostic tests to detect abnormalities in blood vessels.

Clinical

An intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.

Overview

Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

Pharmacology

Indication

Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

Pharmacodynamic

Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum album... Read more

Mechanism of action

Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons result... Read more

Absorption

Information currently not available.

Protein binding

80-90%

Volume of distribution

48 ± 16 mL/kg

Clearance

6.57 ± 0.97 mL/h/kg following the administration of 0.03 mmol/kg.

Half life

18.5 hours

Route of elimination

Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%).

Toxicity

Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²).

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: History of allergy
      • Drugbank Id: DBCOND0108025
  • With Categories:
      • Name: Gadolinium-based Contrast Agent
      • Drugbank Id: DBCAT003476

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Gadofosveset trisodium
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abacavir
Abacavir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Acarbose
Acarbose may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Aceclofenac
Aceclofenac may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Acemetacin
Acemetacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Acetaminophen
Acetaminophen may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Acetazolamide
Acetazolamide may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid
Acetylsalicylic acid may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Aclidinium
Gadofosveset trisodium may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Gadofosveset trisodium may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir
Acyclovir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Adefovir
Adefovir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Albutrepenonacog alfa
Gadofosveset trisodium may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac
Alclofenac may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Aldesleukin
Aldesleukin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Allopurinol
Allopurinol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Allylestrenol
Allylestrenol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Almasilate
Gadofosveset trisodium may decrease the excretion rate of Almasilate which could result in a higher serum level.
Alminoprofen
Alminoprofen may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Almotriptan
Almotriptan may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
5 References
  1. 1 . Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA: 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013 Jun;29(5):1085-94. doi: 10.1007/s10554-013-0192-z. Epub 2013 Mar 21.PubMed: 23515949
  2. 2 . Hrdina L, Kocher M, Herman M, Cerna M, Kozak J, Tudos Z, Mahathmakanthi S, Langova K: Comparison of the quality of lower limb magnetic resonance angiographies performed with different paramagnetic contrast agents in relation to body mass index and ejection fraction. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):164-70. doi: 10.5507/bp.2011.058.PubMed: 22660207
  3. 3 . Thouet T, Schnackenburg B, Kokocinski T, Fleck E, Nagel E, Kelle S: Visualization of chronic myocardial infarction using the intravascular contrast agent MS-325 (gadofosveset) in patients. ScientificWorldJournal. 2012;2012:236401. doi: 10.1100/2012/236401. Epub 2012 Mar 12.PubMed: 22536125
  4. 4 . Milot L, Haider M, Foster L, McGregor C, Law C: Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: Early experience. J Magn Reson Imaging. 2012 Sep;36(3):738-42. doi: 10.1002/jmri.23650. Epub 2012 Apr 5.PubMed: 22488745
  5. 5 . Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p.PubMed: 19222207